NeuroScientific Biopharmaceuticals (ASX:NSB) began the transfer of its patented manufacturing process for its mesenchymal stromal cells from cell and tissue therapy at the Royal Perth Hospital in Western Australia to Q-Gen Cell Therapeutics (Q-Gen) of QIMR Berghofer Medical Research Institute in Brisbane, Queensland, according to a Thursday Australian bourse filing.
Q-Gen holds a Therapeutic Goods Administration license for cell therapy manufacture, and the commencement of the technology transfer to Q-Gen is an important milestone for NeuroScientific to establish its cell manufacturing.
NeuroScientific's unit, Isopogen Australia Opco, previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen would undertake manufacturing process development, scale-up, and clinical grade manufacture of the firm's proprietary StemSmart platform technology.
Its shares rose 4% in recent trade.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。